Honasa Buys 58% of Fluence Pharma for Rs 135 Cr, Launches Honasa Health for Nutraceuticals
Mamaearth parent Honasa Consumer is acquiring 58% of Fluence Pharma at a Rs 135 crore enterprise value, with the remaining stake to be absorbed over 5-7 years. It has also incorporated B2C subsidiary Honasa Health to enter the nutraceuticals category, signaling a push beyond personal care.
Honasa Consumer (Mamaearth parent) approved acquiring 58% of Fluence Pharma at Rs 135 crore EV, with rest absorbed over 5-7 years, and incorporated B2C subsidiary Honasa Health for nutraceuticals. Advit Jewels and Waterways Leisure cruise IPOs also underway.